MedPath

NAPP PHARMACEUTICALS LIMITED

🇬🇧United Kingdom
Ownership
-
Employees
-
Market Cap
-
Website

A Study to Compare Oxycodone/Naloxone Prolonged Release Against Codeine/Paracetamol in the Treatment of Moderate to Severe Chronic Low Back Pain or Pain Due to Osteoarthritis

Phase 4
Completed
Conditions
Osteoarthritis
Back Pain
Interventions
Drug: Oxycodone/Naloxone
Drug: Codeine/Paracetamol
First Posted Date
2008-11-04
Last Posted Date
2011-11-02
Lead Sponsor
Napp Pharmaceuticals Limited
Target Recruit Count
247
Registration Number
NCT00784810

Buprenorphine in the Treatment of Osteoarthritis (OA) in the Elderly

Phase 4
Completed
Conditions
Osteoarthritis
Interventions
First Posted Date
2006-05-10
Last Posted Date
2011-06-14
Lead Sponsor
Napp Pharmaceuticals Limited
Target Recruit Count
219
Registration Number
NCT00324038
Locations
🇬🇧

Napp Pharmaceuticals Ltd, Cambridge, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath